PMID: 9184614May 1, 1997Paper

Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia

The Journal of Clinical Psychiatry
P V TranG M Kiesler

Abstract

A relative lack of extrapyramidal symptoms (EPS, i.e., the syndromes of dystonia, parkinsonism, akathisia, dyskinesia) is one criterion used to determine whether an antipsychotic is "atypical." The extrapyramidal symptom profiles of the novel antipsychotic olanzapine and the conventional antipsychotic haloperidol were compared in a population of 2606 patients from three well-controlled prospective clinical trials. Extrapyramidal symptom data were analyzed for 1796 patients treated with olanzapine (5 to 20 mg/day) and 810 patients treated with haloperidol (5 to 20 mg/day) for up to 6 weeks of therapy. Patients were monitored weekly by three methods of extrapyramidal symptom assessment: (1) detection of extrapyramidal adverse events (signs and symptoms) by casual observation, nonprobing inquiry, and spontaneous report; (2) objective rating scale scores: and (3) use of concomitant anticholinergic medications. Emergence of EPS was assessed by (1) analysis of the incidence of extrapyramidal syndrome categories based on adverse events, (2) the incidence of extrapyramidal syndromes based on categorical analysis of rating scale scores, (3) analysis of mean maximum change in rating scale scores, and (4) categorical analysis of anticholi...Continue Reading

Citations

Sep 21, 2007·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Reinhard SchnabelFlorian Eichmann
Jan 25, 2012·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Dustin M Hipp, E Wesley Ely
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Frank P BymasterDavid L Mckinzie
Jan 31, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Martin R K DossenbachUNKNOWN Olanzapine HGCH Study Group
Oct 6, 1998·European Journal of Pharmacology·A Newman-TancrediM J Millan
Dec 24, 2003·Journal of Psychiatric Research·Dilip V Jeste, Christian R Dolder
Oct 30, 1998·Journal of Psychiatric Research·M D Jibson, R Tandon
Mar 26, 2002·Clinical Therapeutics·Andrew J CutlerJohn A Tumas
Oct 9, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Vassilis P KontaxakisKonstantinos G Paplos
Apr 15, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Julio BobesMiguel Gutiérrez
Dec 31, 2002·Psychoneuroendocrinology·H Nasrallah
Dec 11, 1999·Schizophrenia Research·K TuiskuR Rimon
Oct 5, 2001·European Psychiatry : the Journal of the Association of European Psychiatrists·S MoritzM Krausz
Nov 26, 2002·Journal of the American Academy of Child and Adolescent Psychiatry·Scott W WoodsThomas H McGlashan
Dec 1, 2005·International Clinical Psychopharmacology·Yoriko Kozuki, Karen G Schepp
Jun 27, 2000·Australian and New Zealand Journal of Medicine·A S Granger, H C Hanger
Aug 1, 2007·Healthcare Policy = Politiques De Santé·Daria O'ReillyPatrick Parfrey
Jul 23, 1999·Pharmacotherapy·Y C ChanG Neufeld
Sep 24, 1999·Current Medical Research and Opinion·B Green
May 24, 2011·Pharmacological Reports : PR·Elżbieta NowakowskaCzesław Sadowski
Jan 19, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Huijie LiQi-Yong Gong
Apr 21, 2007·Psychiatry Research·Marc De HertJozef Peuskens
Dec 3, 2005·Child and Adolescent Psychiatric Clinics of North America·Harvey N KranzlerSanjiv Kumra
May 3, 2000·Lancet·S W Mikhail, H G Kennedy
Jan 21, 2015·Psychiatry and Clinical Neurosciences·Toshiya Inada, Ataru Inagaki
Oct 20, 1998·Journal of the American Geriatrics Society·S Gaile, J A Noviasky
Feb 13, 2001·Biological Psychiatry·G D TollefsonUNKNOWN Lilly Resistant Schizophrenia Study Group
Nov 23, 2006·European Psychiatry : the Journal of the Association of European Psychiatrists·J-M Vanelle, S Douki
Feb 9, 2017·ACS Chemical Neuroscience·Marshall W TylerStephen J Haggarty
Mar 28, 2003·The Annals of Pharmacotherapy·Benedetta Santarlasci, Andrea Messori

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.